Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney

Saadh M.J.; Alhuthali H.M.; Gonzales Aníbal O.; Asenjo-Alarcón J.A.; Younus D.G.; Alhili A.; Adhab Z.H.; Alsalmi O.; Gharib A.F.; Pecho R.D.C.; Akhavan-Sigari R. · Cell Biology International (2024) · DOI: 10.1002/cbin.12098

Resumen

Mesenchymal stem cells (MSCs) are recognized for their remarkable ability to differentiate into multiple cell types. They are also known to possess properties that can fight cancer, leading to attempts to modify MSCs for use in anticancer treatments. However, MSCs have also been found to participate in pathways that promote tumor growth. Many studies have been conducted to explore the potential of MSCs for clinical applications, but the results have been inconclusive, possibly due to the diverse nature of MSC populations. Furthermore, the conflicting roles of MSCs in inhibiting tumors and promoting tumor growth hinder their adaptation to anticancer therapies. Antitumorigenic and protumorigenic properties of MSCs in urological cancers such as bladder, prostate, and renal are not as well established, and data comparing them are still limited. MSCs hold significant promise as a vehicle for delivering anticancer agents and suicide genes to tumors. Presently, numerous studies have concentrated on the products derived from MSCs, such as extracellular vesicles (EVs), as a form of cell-free therapy. This work aimed to review and discuss the current knowledge of MSCs and their EVs in urological cancer therapy.

Instituciones: Universidad Nacional Autónoma de Chota